MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/72.5/0.1/20.09.24 | Market Closed - Börse Stuttgart 15:22:09 2024-06-28 EDT | ||
| 0.68 EUR | -1.45% |
|
| Current month | -4.23% | ||
| 3 months | +161.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 0.68 | -1.45% |
| 24-06-27 | 0.69 | -12.66% |
| 24-06-26 | 0.79 | -2.47% |
| 24-06-25 | 0.81 | 0.00% |
| 24-06-24 | 0.81 | +6.58% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 03:22 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | ME1QPD |
| ISIN | DE000ME1QPD5 |
| Date issued | 2023-10-06 |
| Strike | 72.5 $ |
| Maturity | 2024-09-20 (84 Days) |
| Parity | 10 : 1 |
| Emission price | 0.54 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.93 € |
|---|---|
| Lowest since issue | 0.068 € |
| Spread | 0.01 € |
| Spread % | 1.45% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
156.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.69%
- Stock Market
- Warrants
- Warrant
